文献速递炎症性肠病

美国新诊断成人克罗恩病与溃疡性结肠炎的治疗与结局(2007–2023)

Treatment and Outcomes of Crohn's Disease and Ulcerative Colitis in Newly Diagnosed Adults in the United States, 2007 to 2023.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-04-15

基于美国商业保险理赔数据库构建2007–2023年新诊断成人IBD起始队列,克罗恩病3044例、溃疡性结肠炎3893例。克罗恩病5年IBD相关住院、大手术、严重感染风险分别为16%、12%、13%;溃疡性结肠炎分别为11%、6%、10%,西班牙裔患者风险较低。2019–2023年诊断者1年皮质类固醇与先进治疗使用情况被报告,未发现一致的种族、民族、年龄或性别差异。

要点

  • 新诊断克罗恩病5年住院、大手术、严重感染风险分别为16%、12%、13%。
  • 新诊断溃疡性结肠炎5年住院、结肠切除、严重感染风险分别为11%、6%、10%。
  • 西班牙裔溃疡性结肠炎患者上述风险低于白人患者,先进治疗使用也较低。

核心结论

  • 在美国当代多样化商业保险新诊断成人IBD队列中,过度使用皮质类固醇在近期减少,同时先进治疗启动更早。
  • 未发现一致的种族和民族、年龄或性别差异。

研究设计与样本

  • 使用OptumLabs Data Warehouse行政理赔数据库构建2007–2023年医生诊断IBD的起始队列。
  • 克罗恩病3044例,诊断年龄39±15岁,男性47%,白人83%、黑人7.5%、西班牙裔7.1%,平均随访4.3±3.1年。
  • 溃疡性结肠炎3893例,诊断年龄41±14岁,男性52%,白人80%、黑人7.2%、西班牙裔8.2%,平均随访4.2±3.0年。

主要发现

  • 克罗恩病5年IBD相关住院、大手术、严重感染风险分别为16%、12%、13%,无一致的种族和民族、年龄或性别差异。
  • 克罗恩病2019–2023年诊断者1年皮质类固醇累积使用44%(22%使用≥2疗程),先进治疗累积使用53%,无显著种族和民族、年龄或性别差异。
  • 溃疡性结肠炎5年IBD相关住院、结肠切除、严重感染风险分别为11%、6%、10%,西班牙裔患者风险低于白人患者。
  • 溃疡性结肠炎2019–2023年诊断者1年皮质类固醇累积使用47%(26%使用≥2疗程),先进治疗累积使用27%,近期先进治疗启动更早,西班牙裔患者先进治疗使用较低。

临床怎么用

  • 临床可参考新诊断成人IBD的5年住院、手术和严重感染风险,用于患者咨询和风险分层。
  • 关注西班牙裔溃疡性结肠炎患者风险较低及先进治疗使用较低的现象,个体化评估治疗可及性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We examined treatment and outcomes of inflammatory bowel diseases (IBDs) in a contemporary and diverse cohort of adults with newly diagnosed IBD in a large, commercially insured United States population. METHODS: Using an administrative claims database (OptumLabs Data Warehouse), we created an inception cohort of physician-diagnosed IBD between 2007 and 2023. We examined cumulative incidence of hospitalization, surgery, safety events, and medication use in patients with Crohn's disease (CD) and ulcerative colitis (UC). RESULTS: Among 3044 adults with newly diagnosed CD (age at diagnosis, 39 ± 15 years; 47% male; 83% White, 7.5% Black, and 7.1% Hispanic patients) followed over a mean 4.3 ± 3.1 years, 5-year risk of IBD-related hospitalization, major surgery, and serious infections was 16%, 12%, and 13%, respectively, with no consistent racial and ethnic, age, or sex differences. In patients diagnosed between 2019 and 2023, 1-year cumulative use of corticosteroids and advanced therapy was 44% (22% with ≥2 courses) and 53%, respectively, without significant racial and ethnic, age, or sex differences. Among 3893 patients with newly diagnosed UC (age at diagnosis, 41 ± 14 years; 52% male; 80% White, 7.2% Black, and 8.2% Hispanic patients) followed over 4.2 ± 3.0 years, 5-year risk of IBD-related hospitalization, colectomy, and serious infection was 11%, 6%, and 10%, respectively, with lower risk in Hispanic patients (vs White patients). In patients diagnosed between 2019 and 2023, 1-year cumulative use of corticosteroids and advanced therapy was 47% (26% with ≥2 courses) and 27%, respectively, with earlier initiation of advanced therapies in more recent time periods, and with lower utilization of advanced therapies in Hispanic patients. CONCLUSIONS: In a contemporary and diverse cohort of commercially insured adults with newly diagnosed IBD in the United States, excess corticosteroid use is decreasing in recent era, along with early initiation of advanced therapies. No consistent racial and ethnic, age, or sex differences were identified.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ahuja D, Park SK, Qi Y, et al. Treatment and Outcomes of Crohn's Disease and Ulcerative Colitis in Newly Diagnosed Adults in the United States, 2007 to 2023. Clin Gastroenterol Hepatol. 2026. PMID: 41997334. doi:10.1016/j.cgh.2026.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。